NVCR News and Press, NovoCure Limited From 05/24/22

The spread of the “recession” meme is starting to reach a fever pitch (1). In this case, it could counterintuitively be a positive catalyst for the long duration side of the market – ie, the long-term growth bets that are still in their early innings, with big fireworks s...

H.C. Wainwright has initiated NovoCure (NASDAQ:NVCR) with a buy rating citing international expansion of its core business and four phase 3 studies with readouts expected from 2022-2024. The firm has a $115 price target (~76% upside based on Friday's close). Analyst Emily Bodnar said tha...

PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies (“AeroClean” or the “Company”) (Nasdaq: AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce an...

NovoCure's growth has stalled as their GBM market share has gone to 35%-40%, but GBM still offers several additional growth opportunities. Then there are the 4 P3 trials which, if successful, could add additional cancer treatments and dramatically expand the TAM. That's two years ...

Though there are many companies to choose from, I focus on leading innovators with either novel therapeutics or technologies. NovoCure is a premier developer of tumor treating fields that already enjoyed early market success for glioblastoma multiforme and mesothelioma. As the fir...

Even the best stocks can fall on hard times. That's certainly been the case with plenty of biotech stocks over the past 12 months. However, some that have floundered could still be huge winners over the long term. We asked three Motley Fool contributors to pick beaten-down stocks they t...

Image source: The Motley Fool. Novocure (NASDAQ: NVCR) Q1 2022 Earnings Call Apr 28, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Novocure (NVCR) Q1 2022 Earnings Call Transcript

NovoCure Limited (NVCR) Q1 2022 Earnings Conference Call April 28, 2022 8:00 AM ET Company Participants Ingrid Goldberg – Investor Relations Bill Doyle – Executive Chairman Ashley Cordova – Chief Financial Officer Pritesh Shah – Chief Commercial Officer Ely Benaim ...

NovoCure press release (NASDAQ:NVCR): Q1 GAAP EPS of -$0.04 beats by $0.15. Revenue of $137.55M (+2.1% Y/Y) beats by $3.26M. Gross margin for the quarter was 80%.  As of March 31, 2022, there were 3,549 active patients on therapy. Active patients from North America, EMEA and Ja...

Quarterly net revenues of $137.5 million with 80% gross margin Entering a transformational period with multiple clinical catalysts expected in near-term Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2022. Novocure is a globa...